Hepatitis C Virus-Infected Responders and Relapsers to Treatment Show Similar Genetic Profiles of IL28B and IL10 Single Nucleotide Polymorphisms.

Suiane Lima De Souza,Cristiane Alves Villela-Nogueira,Luãnna Liebscher Vidal,Juliene Ramos,Cynthia Chester Cardoso,Marcelo Alves Soares,Renata De Mello Perez,Henrique Sérgio Moraes Coelho,André Felipe Santos

doi:10.1155/2018/2931486

Abstract

Genotype 1 of hepatitis C virus (HCV) is the most prevalent worldwide. Pegylated-interferon and ribavirin therapy is still used in the developing world but has less efficiency in this genotype. Single nucleotide polymorphisms (SNPs) rs12979860 and rs8099917 (IL28B) and rs1800896, rs1800871, and rs1800872 (IL10) are related to treatment outcome, but previous studies clustered nonresponse and relapse patients. The aim of this study is to analyze the frequency of those SNPs in HCV genotype 1 for response, nonresponse, or relapse. Patients were classified according to treatment outcome. Genomic DNA was extracted by blood samples and SNPs were defined by PCR and sequencing. Data analysis was performed with R project. The frequency of rs12979860 CC was similar among responders (0.48) and relapsers (0.46) and lower among nonresponders (0.18). The same trend was observed for rs8099917 TT. rs12979860 CC showed a protective effect for relapsers compared to nonresponders (OR = 0.25) as it occurs with responders (OR = 0.17). Haplotypes 12979860/C rs8099917/T were associated with protection against the nonresponder phenotype compared to responders (OR = 0.27) or relapsers (OR = 0.37). Frequency of rs12979860 and rs8099917 is different between relapsers and nonresponders, but similar between relapsers and responders.

Highlights

130–150 million people, approximately 2% of the world population, are infected with the hepatitis C virus (HCV) worldwide [1]
Independent GWAS studies showed two single nucleotide polymorphisms (SNPs) close to the IL28B gene, rs12979860 C/T and rs8099917 T/G, which are related to the outcome of this treatment [5, 6]
This study describes that only IL28B SNPs showed significant differences in frequency between responders and nonresponders, as well as a protective effect of genotypes rs12979860 CC and rs8099917 TT against a nonresponder phenotype

Summary

Introduction

130–150 million people, approximately 2% of the world population, are infected with the hepatitis C virus (HCV) worldwide [1]. HCV has seven acknowledged genotypes (1–7), but genotype 1 (gen1) is the most prevalent, being responsible for 46% of cases [2] Despite such high prevalence, only 50% of HCV gen1-infected patients achieve sustained virological response (SVR) with pegylatedinterferon (pegIFN) and ribavirin (RBV) dual therapy, while SVR occurs in 80% of patients with other genotypes [3]. Only 50% of HCV gen1-infected patients achieve sustained virological response (SVR) with pegylatedinterferon (pegIFN) and ribavirin (RBV) dual therapy, while SVR occurs in 80% of patients with other genotypes [3] This therapeutic regimen has been overcome by the development of direct acting antivirals (DAA), it is still widely used in the developing world. Some studies showed an association with treatment [7, 8], but others have shown no difference between failure patients and patients who achieve SVR [9, 10]

Objectives

Methods

Results

Conclusion